Document is current
Any future updates will be listed below
-
Authors
Yang, Ning http://orcid.org/0000-0001-5121-7208
Luna, Joseph M. http://orcid.org/0000-0003-2415-9203
Dai, Peihong
Wang, Yi http://orcid.org/0000-0002-4046-9511
Rice, Charles M. http://orcid.org/0000-0003-3087-8079
Deng, Liang http://orcid.org/0000-0002-8467-9342
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R56AI095692, R01 AI091707)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 16 November 2020
Accepted: 2 March 2022
First Online: 29 March 2022
Competing interests
: Memorial Sloan Kettering Cancer Center filed a patent application for the use of recombinant MVA∆C7L or VACV∆C7L as monotherapy or in combination with immune checkpoint blockade for solid tumors and vaccine applications. L.D. and N.Y. are co-founders of IMVAQ Therapeutics and C.M.R. is a member of the scientific advisory board of IMVAQ Therapeutics. The remaining authors declare no competing interests.
